In this episode of the podcast, we focus on adverse events (AEs) and toxicities in the post-CAR T-cell therapy setting. First, Marion Subklewe, MD, Ludwig Maximilians University of Munich, Munich, Germany, outlines the main factors contributing to the observed reduction in the incidence of higher-grade CRS and ICANS following CAR-T. Following this, Eleftheria Kampouri, MD, University of Lausanne, Lausanne, Switzerland, provides insights into infection prevention post–CAR-T and antibiotic use in febrile patients, and Birte Friedrichs, MD, Düsseldorf University Hospital, Düsseldorf, Germany, discusses the misconception among physicians that the side effects of CAR-T are too severe for their patients with diffuse large B-cell lymphoma (DLBCL).

You will then hear from Megan Melody, MD, Northwestern University Feinberg School of Medicine, Chicago, IL, who shares advice for community physicians monitoring patients for less common toxicities following CAR-T, and Kenneth Lim, MBBS, Australian Centre for Blood Diseases, Monash University, Melbourne, Australia, who highlights AEs that physicians should be aware of when treating patients with multiple myeloma with ciltacabtagene autoleucel (cilta-cel).